

Updated: 9 November 2021

## Information about COVID-19 Vaccination Information for Patients with Gastrointestinal or Liver Diseases on Immunosuppressive Therapy

Pfizer COMIRNATY mRNA
vaccination prevented symptomatic
COVID-19 in 95%
2 doses given 3-6 weeks apart
Age 12 and over

Moderna SPIKEVAX mRNA
vaccination prevented
symptomatic COVID-19 in 96%
2 doses given 4 weeks apart
Age 12 and over

AstraZeneca VAXZEVRIA viral vector vaccination prevented symptomatic COVID-19 in 82%
2 doses given 6-12 weeks apart Age 18 and over

All vaccinations have been shown to prevent severe infection and hospitalisation after completing the recommended doses

Protection against COVID-19 may not be until 14 days after the second dose

The COVID-19 vaccinations are considered safe and effective and recommended for patients experiencing and taking medication for:

- Inflammatory bowel disease (IBD)
- Liver disease
- Liver transplantation
- If you are pregnant or pregnancy planning, an mRNA vaccine (Pfizer/Moderna) is recommended
- If you are aged between 12-18, mRNA vaccines (Pfizer/Moderna) are approved and recommended
- COVID-19 vaccines are currently not approved in Australia for people < 12 years of age</li>
- Some medications may decrease how well the COVID-19 vaccine works. Discuss with your medical specialist
  the timing of your vaccination if you are taking more than 20mg of prednisolone daily
- COVID-19 vaccination can be given at any time in relation to biologic medicines

You may be eligible for a third vaccine dose 2-6 months after the second dose in some circumstances. This vaccine should ideally be an mRNA vaccine (Pfizer or Moderna). Eligibility criteria includes:

- High dose or combination immunosuppressant medications
- High dose prednisolone

If you are not eligible for a third COVID-19 vaccine you will be eligible for a booster vaccination. A booster vaccine occurs more than 6 months after your second dose of primary vaccination. Comirnaty (Pfizer) is the preferred booster vaccine. Eligibility criteria include:

- 18 years or older
- 6 months or more after completion of your primary two COVID-19 vaccination doses
- COVID-19 vaccination is not currently available to children < 12 years of old. However, children are far less likely than adults to develop severe COVID-19 disease.
- Children on immunosuppression do not appear at increased risk of severe COVID-19 compared to agematched controls
- We recommend that siblings and the vast majority of pediatric IBD patients return to school and community activities

What additional steps can I take to protect myself against COVID-19?

- Ensure up to date with Flu vaccination and Pneumococcal vaccination.
- Remain on your medications to keep your condition under control.
- Maintain good hand hygiene.
- Help all family members over 12 years of age to be vaccinated.
- Practice social distancing and abide by local state government COVID-19 restrictions in your area

Disclaimer The Gastroenterological Society of Australia (GESA) provides the above advice to guide gastroenterologists and hepatologists who provide care for patients with chronic liver diseases, transplant recipients and IBD during the COVID-19 pandemic. This advice should be modified to fit the context of individual medical practice based on the local policies of the relevant health facilities. Given the rapidly evolving situation, this advice is subject to change, and we will make efforts to update them as needed. Please check the Australian Government website for the latest information on COVID-19 vaccines.